Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|October 14, 2013
The Growth of Accountable Care Organizations
Mark Zitter, CEO at Zitter Health Insights, explains how the growth of Accountable Care Organizations may impact specialty drug management in the near future.
Advertisement
Mark Zitter, CEO at Zitter Health Insights, explains how the growth of Accountable Care Organizations may impact specialty drug management in the near future.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5